FAP and neoplasm: In the MCA205-mFAP model, tumor inhibition with combination 177Lu-FAP-2287 plus anti-PD-1 was observed on day 8 pi with heightened immune responses but by day 13 pi tumor control was lost perhaps in part reflecting immune pro-inflammatory signaling subsiding.